“McKinsey’s $6.44M Settlement in Canadian Drug Lawsuit”

McKinsey & Company agrees to a $6.44 million settlement in a Canadian drug lawsuit related to the opioid crisis.

McKinsey Agrees to Settlement in Canadian Drug Lawsuit

The opioid crisis in Canada, undoubtedly one of the most pressing public health issues, has seen a major development recently. The esteemed consulting firm McKinsey & Company has agreed to be part of a notable settlement proposal concerning a class action lawsuit grounded in the mass proliferation of opioids in Canada. The development is available in detail in this Yahoo News article.

Unpacking the Settlement

According to the report, McKinsey, a firm globally recognized for management consulting, has agreed to the proposal of a $6.44 million settlement. This move would absolve the company from any future lawsuits related to the opioid crisis.

This agreement comes after the company made a similar settlement in the United States, which was worth around $573 million. It is important to note that the approval for this current settlement is still pending from judges who are reviewing Canadian opioid abatement class action lawsuits.

Role of McKinsey in the Opioid Crisis

The article explains how McKinsey allegedly played a role in fueling the opioid epidemic. The consulting firm reportedly advised Purdue Pharma, the manufacturer of the powerful and addictive painkiller OxyContin, on sales strategies. They have been accused of recommending the use of specific sales “turbocharging” tactics that contributed to the opioid crisis.

Key Points from the Article

  • McKinsey has agreed to a settlement proposal of $6.44 million related to the Canadian opioid crisis.
  • The company had earlier agreed to a $573 million settlement in the U.S.
  • The consulting firm is accused of advising sales strategies to Purdue Pharma, contributing to the opioid epidemic.
  • Settlement approval is still pending from judges overseeing the Canadian opioid abatement class action lawsuits.

The Effects of the Canadian Opioid Crisis

In our previous discussions, we’ve outlined the devastating consequences of the opioid crisis on Canadian communities and individuals. Aside from the human toll–thousands of lives lost to opioid addiction–the crisis has led to a dramatic increase in health care expenditures, with significant impacts on the homeless population and a direct correlation to rising crime rates in affected areas.

Canada’s Fight Against the Opioid Crisis

As reports of overdoses and related fatalities continue to escalate, the Canadian government has implemented several strategies to manage the opioid crisis. These include prevention programs, the provision of naloxone (an opioid overdose reversal drug) and support for safe injection sites. However, the settlement from McKinsey noted in the article will add financial fuel to these ongoing efforts.


This recent development in the settlement with McKinsey & Company is a small but significant step in the ongoing fight against the opioid crisis. While the financial compensation cannot undo the damage already done, it is a clear signal to corporations that their role in such public health disasters will not be overlooked. The battle against the opioid epidemic is far from over, but each victory, no matter how small, brings Canada closer to overcoming this tragic crisis.

Note: The Yahoo News article referenced can be found here.


Contact Us:

Please enable JavaScript in your browser to complete this form.
Scroll to Top